
Opinion|Videos|October 6, 2023
Evolving Practice Standards for ER+/HER2- Metastatic Breast Cancer
Author(s)Rebecca A. Shatsky, MD
A medical oncologist discusses challenges with conducting molecular testing and reviews clinical trials focused on biomarkers for patients with ER+/HER2- metastatic breast cancer.
Advertisement
Episodes in this series

Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
ASCO 2026 GU Cancer Highlights: Beyond the LBAs
2
Dr Tolaney on SG + Pembrolizumab Biomarker Data in First-Line mTNBC
3
FDA Approves Generic Eribulin Mesylate for Metastatic Breast Cancer
4
Bispecific ADC Iza-Bren Extends Survival in Advanced TNBC
5


































